• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » An Article Headline about Lemborexant and Sleep Architecture in the Elderly

An Article Headline about Lemborexant and Sleep Architecture in the Elderly

CHPR_OctNovDec_2021_Agitation-scaled.jpg
January 31, 2022
Noah Capurso, MD, MHS

Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Moline M et al, J Clin Sleep Med 2021. Epub ahead of print.

TYPE OF STUDY: Randomized, double-blind, parallel-group study

As we age, sleep architecture worsens in ways that reduce sleep quality, particularly after age 55. Unfortunately, most hypnotics either do not improve sleep quality (eg, the z-hypnotics) or slightly worsen it (eg, the benzodiazepines). Specifically, benzodiazepines in higher doses can reduce stages of sleep that are critical for memory consolidation. Lemborexant (Dayvigo) was approved in 2019 for the treatment of insomnia in adults. Its effects are mediated by dual orexin receptor antagonism. Recently, researchers looked at how sleep architecture changed when older adults took this orexin antagonist.

The study was a secondary analysis of an industry-sponsored, randomized, double-blind trial of 1006 subjects known as SUNRISE 1. All subjects were over age 55 (average 63) and had primary insomnia; the majority were female (86%) and white (72%). The presence of sleep-maintenance insomnia was required; some subjects had sleep-onset insomnia as well. Patients with significant depression, anxiety, or substance use (including caffeine use after 6 pm) were excluded. Also excluded were patients with medical problems that could make hypnotic use unsafe, and those with comorbid sleep disorders (eg, sleep apnea, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, and narcolepsy).

Patients were randomly assigned to one of four conditions: lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg, or placebo. Participants were treated for 30 nights followed by a follow-up period of 14 days before the end-of-study visit. The goal of this secondary analysis was to compare changes in sleep architecture (eg, total sleep time, non-REM sleep, and REM sleep) in older adults with insomnia disorder receiving lemborexant (5 or 10 mg), zolpidem, or placebo.

After a month of treatment, both doses of lemborexant outperformed placebo and zolpidem on measures of sleep architecture. Specific sleep architecture changes included increased total sleep time, non-REM sleep, and REM sleep, as well as reduced REM latency after the first 2 nights of treatment and again after a month of treatment. After 30 days, both doses of lemborexant increased total sleep time by about twice as much as placebo (total sleep increased by 30 minutes on placebo vs 64 minutes on lemborexant 5 mg and 69 minutes on 10 mg). Zolpidem, on the other hand, outperformed placebo in terms of total sleep time and non-REM sleep, but failed to reduce REM latency.

This study is weakened by being a secondary analysis, which makes it more prone to statistical error. Also, while lemborexant did improve sleep architecture, the changes were small and their clinical relevance is unclear. On the other hand, the changes in REM sleep seen here are relevant to age-related memory decline, and separate studies have found that lemborexant protects sleep-dependent memory consolidation in older adults with insomnia (Harand C et al, Front Neurol 2012;3:8).

The benefits seen in this study are consistent with prior research on another orexin antagonist, suvorexant, suggesting the orexin antagonists may have a beneficial class effect on sleep architecture (Snyder E et al, Sleep Med 2016;19:93–100).

TCPR’s Take
Quality is as important as quantity when it comes to sleep, particularly with older adults. Though this is only one study, it’s encouraging to see a hypnotic that improves sleep architecture and may have a positive impact on memory. Lemborexant also belongs to a small group of hypnotics that are relatively safe in older adults (along with suvorexant, ramelteon, and melatonin). Unfortunately, these benefits come at a cost of $10 a pill.

Geriatric Psychiatry
Ncapurso
Noah Capurso, MD, MHS

Approaches to Autism Intervention

More from this author
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto1062975.jpg
    Geriatric Psychiatry

    How to Treat and Assess Delirium in Older Patients

    Treatment of delirium involves correction of the underlying medical disturbance. But how do we best think through potential causes?

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.